Wall Street analysts expect that Assembly Biosciences Inc (NASDAQ:ASMB) will post earnings of ($1.01) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Assembly Biosciences’ earnings, with the highest EPS estimate coming in at ($0.94) and the lowest estimate coming in at ($1.10). Assembly Biosciences posted earnings per share of ($1.03) in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 27th.
According to Zacks, analysts expect that Assembly Biosciences will report full-year earnings of ($3.57) per share for the current financial year, with EPS estimates ranging from ($3.84) to ($3.07). For the next financial year, analysts forecast that the company will post earnings of ($4.16) per share, with EPS estimates ranging from ($5.13) to ($3.26). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.03). Assembly Biosciences had a negative net margin of 647.72% and a negative return on equity of 52.83%. The company had revenue of $4.23 million during the quarter, compared to analyst estimates of $3.45 million.
ASMB has been the topic of a number of analyst reports. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a research report on Thursday, September 19th. ValuEngine upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday. Robert W. Baird set a $74.00 target price on shares of Assembly Biosciences and gave the stock a “buy” rating in a research report on Thursday, October 17th. Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Finally, Mizuho initiated coverage on shares of Assembly Biosciences in a research report on Tuesday, October 15th. They set a “buy” rating and a $20.00 target price on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Assembly Biosciences currently has an average rating of “Buy” and a consensus target price of $36.75.
Shares of NASDAQ:ASMB traded down $0.11 on Friday, reaching $17.64. 253,737 shares of the company’s stock were exchanged, compared to its average volume of 347,374. The company has a fifty day moving average of $19.42 and a 200-day moving average of $14.56. Assembly Biosciences has a twelve month low of $8.13 and a twelve month high of $25.07. The company has a market capitalization of $467.80 million, a price-to-earnings ratio of -4.43 and a beta of 1.60. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.06.
In related news, EVP Richard James Colonno sold 33,061 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $25.00, for a total value of $826,525.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jacqueline Sybil Papkoff sold 1,460 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $21.00, for a total transaction of $30,660.00. Following the completion of the transaction, the senior vice president now directly owns 22,915 shares of the company’s stock, valued at approximately $481,215. The disclosure for this sale can be found here. Corporate insiders own 12.42% of the company’s stock.
A number of large investors have recently modified their holdings of ASMB. Bank of Montreal Can lifted its stake in Assembly Biosciences by 2,084.1% in the 2nd quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 1,834 shares during the last quarter. Quantamental Technologies LLC lifted its stake in Assembly Biosciences by 16,941.2% in the 2nd quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 2,880 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Assembly Biosciences by 9,134.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,293 shares during the last quarter. Millennium Management LLC lifted its stake in Assembly Biosciences by 23.6% in the 3rd quarter. Millennium Management LLC now owns 11,199 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 2,138 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new position in Assembly Biosciences in the 2nd quarter valued at approximately $134,000. 79.56% of the stock is owned by institutional investors and hedge funds.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.